Market Trends of Anal Cancer Industry
Chemotherapy Treatment Segment is Witnessed to Hold the Highest Share During the Forecast Period.
The chemotherapy treatment segment is expected to contribute the highest share of the market growth. Chemotherapy treatment is advantageous for decreasing the cancer cell counts in the body and reducing the progression of the disease with shrinkage in tumors. Adjuvant chemotherapy is chemotherapy that is provided post-surgical procedure or radiation therapy to reduce the tumor cell size, and neo-adjuvant chemotherapy is given to the patients before the surgery and radiation therapy. For instance, in August 2022, a study published in the Journal of Current Treatment Options in Oncology reported that palliative chemotherapy was effective for the management of squamous cell carcinoma of the anal canal with a response rate of 60%. The study involved the use of carboplatin with paclitaxel and modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line therapy to provide promising results to the patients. Therefore, owing to the potential benefits of chemotherapy treatment for minimizing the impact of anal cancer is contributing to the market growth.
Moreover, clinical trials are conducted by the market players for the development of treatment of anal cancer. For instance, in March 2023, Incyte introduced Zynyz (retifanlimab-dlwr) for Merkel Cell Carcinoma and continued to conduct the POD1UM (PD-1 clinical program in multiple malignancies) clinical trial for evaluating the retifanlimab as a monotherapy for patients with squamous cell carcinoma of the anal canal (SCAC). Further, in June 2023, the Memorial Sloan Kettering Cancer Center published the research results in The New England Journal of Medicine, stating that a chemotherapy regimen known as FOLFOX alone before surgery was effective and showed the same results for patients who underwent both chemotherapy and radiation before surgery. Thus, radiation can be skipped to improve patients' quality of life, and chemotherapy is adopted by oncologists, contributing to the market growth.
North America is Anticipated to Occupy the Highest Share During the Forecast Period.
North America is dominating the market and is expected to contribute the same over the forecast period. This is due to the growing burden of anal cancer cases, the increase in research activities, and government initiatives for the development of anal cancer treatments. The growing burden of anal cancer in North America is influencing the market growth. For instance, in March 2023, according to the statistics published by the American Society of Clinical Oncology, estimated that 9,760 adults (3,180 males and 6,580 females) will be diagnosed with anal cancer in the United States in 2023. These estimates show that females are more likely to be diagnosed with anal cancer. Thus, the increasing prevalence of anal cancer among adults in North America contributes to the market growth.
Moreover, research institutes are highly involved in clinical trials for anal cancer therapy development. For instance, in 2023, Mayo Clinic conducted a clinical trial for Nivolumab, which can be given after combined modality therapy for the treatment of patients with high-risk stage II-IIIB anal cancer. Monoclonal antibodies, such as Nivolumab, can decline the spread and growth of cancerous cells, thus being effective in reducing the anal cancer burden. Further, in November 2023, Oncolytics Biotech Inc. introduced the interim results from the Phase 1/2 GOBLET study to determine the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal (SCCA). The results fulfilled the pre-specified requirements for the cohort and exceeded the results from historical controls in similar patient populations.
Furthermore, the significant collaborations and initiatives led by the government to fight against anal cancer influenced the market growth of anal cancer. For instance, in August 2023, Fight Colorectal Cancer collaborated with the National Comprehensive Cancer Network and Pfizer Inc. to optimize biomarker-directed therapy for the treatment of colorectal cancer. Thus, multiple clinical studies and collaborations are conducted to launch new drugs in the market for anal cancer treatment, significantly contributing to the market growth.
